文献速递神经肿瘤

PTPN11变异可能为综合基因组图谱队列中IDH野生型胶质母细胞瘤的预后指标

PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort.
PubMed 文献 · J Neurooncol · 2023-08-08

研究回顾性分析日本全国392例IDH野生型胶质母细胞瘤的综合基因组图谱结果,中位年龄52.5岁,207例(53%)为男性。在286例有生存信息的患者中,20例(6.8%)检出PTPN11变异,与总生存期显著缩短相关(p=0.002),多因素分析显示PTPN11变异和体能状态差为独立预后指标。结论认为PTPN11变异是该队列的负向预后指标。

要点

  • 在286例有生存信息的IDH野生型胶质母细胞瘤患者中,20例(6.8%)检出PTPN11变异,与总生存期显著缩短相关(p=0.002)。
  • 多因素分析显示PTPN11变异和体能状态差为独立预后指标。
  • 在癌症基因组图谱数据队列中未观察到PTPN11变异的预后影响。

核心结论

  • 在综合基因组图谱检测的患者队列中,PTPN11变异是IDH野生型胶质母细胞瘤的负向预后指标。

研究设计与样本

  • 回顾性分析2019年10月至2023年2月间日本全国392例IDH野生型胶质母细胞瘤患者的综合基因组图谱检测结果,数据来自癌症基因组学与先进治疗中心。

主要发现

  • 患者中位年龄为52.5岁,207例(53%)为男性。
  • 在286例有生存信息的患者中,20例(6.8%)检出PTPN11变异,该变异与总生存期显著缩短相关(p=0.002)。
  • 多因素分析显示PTPN11变异和体能状态差为独立预后指标。
  • 在癌症基因组图谱数据队列中未观察到PTPN11变异的预后影响。
  • 为校正左截断和右删失偏倚进行的生存模拟显示PTPN11变异的预后影响仍显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 两个队列中PTPN11变异预后影响的差异可能源于接受综合基因组图谱检测患者的生存偏倚不同,包括左截断和右删失偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioblastoma (GBM) is the most common type of primary malignant brain tumor and has a poor prognosis. Identifying novel targets and stratification strategies is urgently needed to improve patient survival. The present study aimed to identify clinically relevant genomic alterations in IDH-wildtype GBM using data from comprehensive genomic profiling (CGP) assays performed nationwide in Japan. METHODS: The CGP assay results of 392 IDH-wildtype GBM cases performed between October 2019 and February 2023 obtained from the Center for Cancer Genomics and Advanced Therapeutics were retrospectively analyzed. RESULTS: The median patient age was 52.5 years, and 207 patients (53%) were male. In the 286 patients for whom survival information was available, a protein-tyrosine phosphatase non-receptor type 11 (PTPN11) variant detected in 20 patients (6.8%) was extracted as the gene associated with significantly shorter overall survival (p = 0.002). Multivariate analysis demonstrated that the PTPN11 variant and poor performance status were independent prognostic indicators. In contrast, no prognostic impact was observed in the cohort in The Cancer Genome Atlas data. The discrepancy in the prognostic impact of the PTPN11 variant from these two pools might have resulted from differences in the biases affecting the survival of patients who underwent a CGP assay, including left-truncation and right-censored bias. However, survival simulation done to adjust for these biases showed that the prognostic impact of the PTPN11 variant was also significant. CONCLUSIONS: The PTPN11 variant was a negative prognostic indicator of IDH-wildtype GBM in the patient cohort with the CGP assay.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Otani R, Ikegami M, Yamada R, et al. PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort. J Neurooncol. 2023. PMID: 37552362. doi:10.1007/s11060-023-04411-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。